Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Xponance Inc.

Xponance Inc. grew its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,026 shares of the medical instruments supplier's stock after purchasing an additional 1,363 shares during the period. Xponance Inc.'s holdings in Becton, Dickinson and Company were worth $9,308,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Bank of Jackson Hole Trust purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company in the 4th quarter worth about $29,000. Picton Mahoney Asset Management increased its stake in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after acquiring an additional 54 shares in the last quarter. Hopwood Financial Services Inc. bought a new position in shares of Becton, Dickinson and Company in the 4th quarter worth about $39,000. Finally, Versant Capital Management Inc grew its position in Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier's stock valued at $47,000 after purchasing an additional 73 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Richard Byrd sold 1,940 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the transaction, the executive vice president now owns 7,411 shares of the company's stock, valued at $1,666,808.01. This represents a 20.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,984 shares of company stock worth $1,147,865 over the last three months. 0.36% of the stock is owned by corporate insiders.

Remove Ads

Becton, Dickinson and Company Price Performance

BDX traded down $1.22 during trading hours on Friday, hitting $230.63. The company's stock had a trading volume of 4,372,181 shares, compared to its average volume of 1,539,839. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The business's 50-day moving average price is $232.58 and its 200-day moving average price is $232.04. The stock has a market cap of $66.22 billion, a price-to-earnings ratio of 38.31, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a stock buyback plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.80%. Becton, Dickinson and Company's payout ratio is currently 69.10%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BDX. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a report on Tuesday, January 28th. StockNews.com upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Wednesday, March 5th. Finally, Barclays raised their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.